Molecular mechanism of resistance to antifolates, a review

• Autorzy: Banerjee D. , Ercikan-Abali E. , Waltham M. , Schnieders B. , Hochhauser D. , Li W.W. , Fan J. , Gorlick R. , Goker E. , Bertino J.R.
• Języki publikacji: EN

Abstrakty

EN

Methotrexate (MTX) is a clinically important antifolate that has been used in combination with other chemotherapeutic agents in the treatment of malignancies including acute lymphocytic leukemia, osteosarcoma, carcinomas of the breast, head and neck, choriocarcinoma and non-Hodgkin's lymphoma. The primary target of MTX is the enzyme dihydrofolate reductase (DHFR) which catalyzes the reduction of folate and 7,8-dihydrofoIate to 5,6,7,8-tetrahydrofolate. Understanding of MTX action has revealed how cells acquire resistance to this drug. The four known mechanisms of MTX resistance are a decrease in the uptake of the drug, a decrease in the retention of the drug due to defective polyglutamylation or an increase in polyglutamate breakdown, an increase in the enzyme activity and a decrease in the binding of MTX to DHFR. The molecular basis for some of these mechanisms has been elucidated in MTX resistant cell lines; in particular the occurrence of gene amplification resulting in increased DHFR and point mutations resulting in altered DHFR with reduced affinity for MTX. Cloning of the human folylpolyglutamate synthase gene and the reduced folate transport gene have been reported recently and should facilitate the identification of the molecular basis of these resistant phenotypes. DHFR protein has been shown to regulate its synthesis by exerting an inhibitory influence on its own translation. Addition of MTX relieves this inhibition thus providing a possible molecular explanation for the rapid rise in DHFR activity noted in some cells after MTX administration. Alterations in genes involved in regulating the cell cycle such as cyclin D1 and the retinoblastoma (Rb) gene have also been shown to influence cellular response to MTX. Overexpression of cyclin D1 in HT1080, a human fibrosarcoma cell line, results in decreased MTX sensitivity. The molecular basis of this observation is under investigation. Abnormalities in the Rb gene may also have profound effects on MTX sensitivity. Rb interacts with the family of transcription factors called E2F reducing transcription of genes that contain E2F binding sites in the promoter regions e.g. DHFR. When Rb is deleted or rendered nonfunctional levels of "free" or unbound E2F are high resulting in enhanced transcription of genes such as DHFR. This results in increased DHFR protein and may lead to MTX resistance. As the knowledge regarding mechanisms of resistance increases newer approaches to circumvent such resistance or to target resistant cells can be undertaken.

Słowa kluczowe

EN

gene therapy; methotrexate; drug resistance; cell cycle; molecular mechanism; antifolate

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 1995
• Tom: 42
• Numer: 4
• Opis fizyczny: p.457-464

Twórcy

autor

Banerjee D.

• Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA

autor

Ercikan-Abali E.

autor

Waltham M.

autor

Schnieders B.

autor

Hochhauser D.

autor

Li W.W.

autor

Fan J.

autor

Gorlick R.

autor

Goker E.

autor

Bertino J.R.

Bibliografia

• 1. Bertino, J.R. (1993) Karnofsky Memorial Lecture. Ode to methotrexate. /. Clin. Oncol. 11, 5-14.
• 2. Blakley, R.L. (1984) Dihydrofolate reductase; in Folates and Pterins. Chemistry and Biochemistry of Folates. Dihydrofolate reductase (Blakley, R.L. & Benkovic, S.J., eds.) vol 1, pp. 191-251, Wiley, New York.
• 3. Goldman, I.D. & Matherly, L.H. (1986) The cellular pharmacology of methotrexate; in Mem­brane Transport of Antineoplastic Agents. Inter­national Encyclopedia of Pharmacology and Therapeutics (section 118) (Goldman, I.D., ed.) p. 283, Pergamon, Oxford, U.K.
• 4. McGuire, J.J., Hsieh, P., Coward, J.K. & Bertino, J.R. (1980) Enzymatic synthesis of folylpo- lyglutamates. Characterization of the reaction and its products.}. Biol. Chem. 255, 5776-5788.
• 5. Whitehead, V.M., Rosenblatt, D„ Vuchich, M.J., Shuster, J.J., Witte, A., Beaulieu, D. (1990) Me­thotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood ALL: A pilot prognostic factor analysis. Blood 76,44-50.
• 6. Allegra, C.J., Chabner, B.A., Drake, J.C., Lutz, R„ Rodbard, D. & Jolivet, J. (1985) Enhanced inhibition of thymidylate synthase by metho­trexate polyglutamates. J. Biol. Chem. 260, 9720-9726.
• 7. Allegra, C.J., Drake, J.C., Chabner, B.A. (1985) Inhibition of phosphoribosyl-aminoimida- zolecarboxamide transformylase by metho­trexate and dihydrofolic acid polyglutamate. Proc. Natl. Acad. Sci. U.S.A. 82,4881-4885.
• 8. Jolivet, J., Cowan, K.H., Curt, G.A. & Chabner, B.A. (1983) The pharmacology and clinical use of methotrexate. N. Engl. ]. Med. 309,1094-1103.
• 9. Silnik, M., Reddel, R., Bethel, M. & Rowe, P.B. (1975) Gamma-glutamyl hydrolase (conjugase) purification and properties of the bovine hepatic enzyme. J. Biol. Chem. 250,5982-5994.
• 10. Elsenhans, B., Ahmad, O. & Rosenberg, I. (1984) Isolation and characterization of pteroylglu- tamate hydrolase from rat intestinal mucosa. /. Biol. Chem. 259,6364^6368.
• 11. Chandler, C., Wang, T. & Halsted, C. (1986) Pte- roylglutamate hydrolase from human jejunal brush borders: purification and characte­rization. J. Biol. Chem. 261, 928-933.
• 12. Wang, T., Chandler, C. & Halsted, C. (1986) Intracellular pteroylglutamate hydrolase from human jejunal mucosa: isolation and chara­cterization. ]. Biol. Chem. 261, 13551-13555.
• 13. Schweitzer, B.I., Dicker, A.P. & Bertino, J.R. (1990) Dihydrofolate reductase as a therapeutic target. FASEB }. 4, 2441-2452.
• 14. Trippett, T., Schlemmer, S., Elisseyeff, Y., Goker, E., Wachter, M., Steinherz, P., Tan, C., Berman, E., Wright, J.S., Rosowsky, A., Schweitzer, B.I. & Bertino, J.R. (1992) Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute leukemia. Blood 80,1158-1162.
• 15. Matherly, L.H., Angeles, S.M. & Czajkowski, C.A. (1992) Characterization of transport mediated methotrexate resistance in human tumor cells with antibodies to the membrane carrier for methotrexate and tetrahydrofolate cofactors. /. Biol. Chem. 267, 23253-23260.
• 16. Matherly, L.H., Taub, J.W., Ravindranath, Y. Proefke, S., Wong, S.C., Gimotty, P., Buck, S., Wright, J.S. & Rosowsky, A. (1995) Elevated dihydrofolate reductase and impaired metho­trexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood 85,500-509.
• 17. Williams, F.M., Murray, R.C., Underhill, T.M. & Flintoff, W.F. (1994) Isolation of a hamster cDNA clone coding for a function involved in metho­trexate uptake. /. Biol. Chem. 269,5810-5816.
• 18. Dixon, K.H., Lanpher, B.C., Chiu, J., Kelley, K. & Cowan, K.H. (1994) A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells. J. Biol. Chem. 269,17-20.
• 19. Williams, F.M. & Flintoff, W.F. (1995) Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake./. Biol. Chem. 270, 2987-2992.
• 20. Marger, M.D. & Saier, M.H., jr. (1993) A major superfamily of transmembrane facilitators that catalyze uniport, symport and antiport. Trends Biochem. Sci. 18,13-20.
• 21. Goker, E., Lin, J.T., Trippett, T., Elisseyeff, Y., Tong, W.P., Niedzwiecki, D., Tan, C., Steinherz, P., Schweitzer, B.I. & Bertino, J.R. (1993) Decre­ased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. Leukemia 7,1000-1004.
• 22. Lin, J.T., Tong, W.P., Trippett, T., Niedzwiecki, D.,Tao, Y., Tan, C., Steinherz, P., Schweitzer, B.I. & Bertino, J.R. (1991) Basis for natural resistance to methotrexate in human acute non-lympho- cytic leukemia. Leukemia Res. 15,1191-1196.
• 23. Synold, T.W., Relling, M.V. & Boyett, J.M. (1994) Blast cell methotrexate polyglutamale accumu­lation in vivo differs by lineage, ploidy, and me­thotrexate dose in acute lymphoblastic leuke­mia./. Clin. Invest. 94,1996-2001.
• 24. Barredo, J.C., Synold, T.W. & Laver, J. (1994) Differences in constitutive and post-metho- trexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 84, 564-569.
• 25. Goker, E., Kheradpour, A., Wallham, M.C., Banerjee, D., Tong, W.P, Elisseyeff, Y. & Bertino, J.R. (1995) Acute monocytic leukemia: a myeloid subset that may be sensitive to methotrexate. Leukemia 9, 274-276.
• 26. Galivan, J., Johnson, T., Rhee, M., McGuire, J.J., Priest, D.G. & Kesevan, V. (1987) The role of folylpolyglutamate synthetase and gamma- -glutamylhydrolase in altering cellular folyl- and antifolyl-polyglulamates. Adv. Enz. Reg. 26, 147-155.
• 27. Garrow, T.A., Admon, A. & Shane, B. (1992) Expression cloning of a human cDNA encoding folylpoly(-glutamate) synthetase and determi­nation of its primary structure. Proc. Natl. Acad. Sci. U.S.A. 89, 9151-9155.
• 28. Lenz, H.J., Danenberg, K., Schnieders, B., Goker, E., Peters, G.J., Garrow, T., Shane, B., Bertino, J.R. & Danenberg, PV. (1994) Quantitative analysis of folylpolyglutamate synthetase gene expres­sion in tumor tissues by the polymerase chain reaction: marked variation of expression among leukemia patients. Oncol. Res. 6,329-335.
• 29. Samuels, L.L., Goûtas, L.J., Priest, D.G., Piper, J.R. & Sirotnak, P.M. (1986) Hydro lytic cleavage of methotrexate-polyglutamates bv folylpoly- glulamyl hydrolase derived from various tu­mors and normal tissues of the mouse. Cancer Res. 46, 2230-2235.
• 30. Rhee, M.S., Wang, Y., Gopal Nair, M. & Galivan, J. (1993) Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydro­lase activity. Cancer Res. 53, 2227-2230.
• 31. Carman, M.D., Schornagel, J.H., Rivest, R.S., Srimatkandada, S., Portlock, C.S., Duffy, T. & Bertino, J.R. (1984) Resistance to methotrexate due to gene amplification in a patient with acute leukemia. /. Clin. Oncol. 2, l(>-20.
• 32. Horns, R.C., Dower, W.J. & Schimke, R.T. (1984) Geneamplification in a leukemia pa tient treated with methotrexate./. Clin. Oncol. 2, 2-5.
• 33. Trent, J.M., Buick, R.N., Olson, S., Horns, R.C. & Schimke, R.T. (1984) Cytologic evidence for gene amplification in methotrexate resistant cells obtained from a patient with ovarian adenocarcinoma. J. Clin. Oncol. 2,8-12.
• 34. Curt, G.A., Corney, D.N., Cowan, K.H., Jolivet, J., Bailey, B.D., Drake, J.C., Kao-Shan, C.S., Minna, J. & Chabner, B.A. (1983) Unstable methotrexate resistance in human small cell lung cancer associated with double minute chromosomes. New Engl. J. Med. 308, 99-104.
• 35. Goker, E., Wallham, M.C., Kheradpour, A., Trippett, T., Majumdar, M., Elisseyeff, Y., Schnieders, B., Steinherz, P., Tan, C, Berman, E. & Bertino, J.R. (1995) Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood 86, 677-684.
• 36. Simonsen, C.C. & Levinson, A.D. (1983) Isola­tion and expression of an altered dihydrofolate reductase cDNA. Proc. Natl. Acad. Sci. U.S.A. 80, 2495-2499.
• 37. Haber, D.A., Beverly, S.M., Kiely, M.I,. & Schim­ke, R.l". (1981) Properties of an altered dihydro­folate reductase encoded by amplified genes in cultured mouse fibroblasts. /. Biol. Chem. 256, 9501-9510.
• 38. Srimatkandada, S., Schweitzer, B.I., Moroson, B.A., Dube, S. & Bertino, J.R. (1989) Ampli­fication of a polymorphic dihydrofolate re­ductase gene expressing an enzyme with a decreased binding to MTX in a human colon carcinoma cell line, HCT-8R4 resistant to this drug. /. Biol. Chem. 264, 3524-3528.
• 39. Melera, P.W., Da vide, J.P., Hession, C.A. & Scotto, K.W. (1984) Phenotypic expression in Escherichia coli and sequence of two Chinese hamster lung cDNA encoding different dihy­drofolate reductase. Mol. Cell. Biol. 4, 38-48.
• 40. Dicker, A.P., Volkenandt, M.V., Schweitzer, 13.1., Banerjee, D. & Bertino, J.R. (1990) Identification and characterization of a mutation in the dihy­drofolate reductase gene from methotrexate resistant CHO cell line Pro-3 MTX Rill. /. Biol. Chem. 265, 8317-8321.
• 41. Mclvor, R.S. & Simonsen, C.C. (1990) Isolation and characterization of a variant dihydrofolate reductase cDNA from the methotrexate resis­tant murine L5178Y cells. Nucleic Acids Res. 18, 7025-7032.
• 42. Hyde, J.E. (1990) The dihydrofolate reductase- -thymidylate synthase gene in the drug resis­tance of malaria parasites. Pharmacol. Ther. 48, 45-59.
• 43. Nevins, J.R. (1992) E2F; a link between the Rb tumor suppressor protein and viral oncopro­teins. Science 258, 424-427.
• 44. Li, W.W., Fan, J., Hochhauser, D., Banerjee, D., Zieliński, Z., Almasan, A., Yin, Y., Kelly, R., Wahl, G.M. & Bertino, J.R. (1995) Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc. Natl. Acad. Sci. U.S.A. 92,10436-10440.
• 45. Livingstone, L.R., White, A., Sprouse, J., Liva- nos, E., Jacks, T. & Tlsty, T. (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild type p53. Cell 70, 923-930.
• 46. Yin, Y., Tainsky, M.A., Bischoff, F.Z., Strong, L.C. & Wahl, G.M. (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70, 937-944.
• 47. Bertino, J.R., Donohue, D.M., Simmons, B., Gabrio, B.W., Silber, R. & Huennekens, F.M. (1963) The induction of dihydrofolate reductase in leukocytes and erythrocytes of patients treated with methotrexate. J. Clin. Invest. 423, 466-475.
• 48. Hillcoat, B.L., Swett, V. & Bertino, J.R. (1967) Increase of dihydrofolate reductase activity in cultured mammalian cells after exposure to methotrexate. Proc. Natl. Acad. Sci. U.S.A. 58, 1632-1637.
• 49. Chu, E., Koeller, D.M., Casey, J.L., Drake, J.C., Chabner, B.A., Elwood, P.C., Zinn, S. & Allegra, C.A. (1991) Autoregulation of human thymi- dylate synthase messenger RNA translation by thvmidylate. Proc. Natl. Acad. Sci. U.S.A. 88, 8977-8981.
• 50. Ercikan, E., Banerjee, D., Waltham, M.C., Schnieders, B„ Scotto, K.W. & Bertino, J.R. (1993) Translational regulation of the synthesis of dihydrofolate reductase; in Chemistry and Biol- ogy ofPteridines and Folates (Ayling, J.E., ed.) pp. 537-540, Plenum Press.
• 51. Korsmeyer, S.J. (1992) Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80, 879-886.
• 52. Miyashita, T. & Reed, J.C. (1993) Bcl-2 onco­protein blocks chemotherapy induced apo- ptosis in a human leukemia cell line. Blood 81, 151-156.
• 53. Delia, D., Aiello, A., Soligo, D., Fontanel], E., Melani, C, Pezzella, R, Pierotti, M.A. & Delia Porta, G. (1992) Bcl-2 proto-oncogene expres­sion in normal and neoplastic human myeloid cells. Blood 79,1291-1295.
• 54. Lacerda, J.F., Goker, E., Kheradpour, A., Dennig, D., Elisseyeff, Y., Jagiello, C., O'Reilly, R.J. & Bertino, J.R. (1995) Selective treatment of SCID mice bearing methotrexate transport resistant human ALL tumors with trimetrexate and leucovorin. Blood 85, 2675-2679.
• 55. Flasshove, M., Banerjee, D., Mineishi, S., Li, M.-X., Bertino, J.R. & Moore, M.A.S. (1995) Ex vivo expansion and selection of human CD34+ peripheral blood progenitor cells after intro­duction of a mutated dihydrofolate reductase cDNA via retroviral gene transfer. Blood 85, 566-574.
• 56. Banerjee, D., Zhao, S.C., Li, M.-X., Schweitzer, B.I., Mineishi, S. & Bertino, J.R. (1994) Gene therapy utilizing drug resistance genes: a review. Stem Cells 12,378-385.